Changchun High & New Technology Industry (Group) Inc. provided earnings guidance for the year 2020. For the year, the company expects earnings in range from CNY 3.017 billion to CNY 3.195 billion, a year-on-year increase of 70% to 80% over the same period last year. Earnings per share are expected to be in the range from CNY 7.46 to CNY 7.89. The main reasons are as follows; One is that the backbone pharmaceutical enterprises under the Company's control, namely GeneScience Pharmaceuticals Co. Ltd. and Changchun BCHT Biotechnology Co. Ltd, had a certain increase in revenue .Another reason is that the Company implemented a major asset restructuring in 2019, where the remaining 29.5% minority interest in GeneScience Pharmaceuticals Co. Ltd. was consolidated from November 2019 onwards, which changed the original 70% to a consolidated caliber of 99.5%, therefore contributed to the increment in the Company’s financial data in the financial year of 2020.